ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2346

SLE Medication Usage and Organ Damage Among Adult SLE Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years

Zahi Touma1, Cristina Arriens2, Christine Henning3, Angela Carroll3, Paula Curtis4, Roger A. Levy5 and William Stohl6, 1University of Toronto, Toronto, ON, Canada, 2Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, 3GlaxoSmithKline, US Medical Affairs, Durham, NC, 4GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, 5GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 6University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA

Meeting: ACR Convergence 2023

Keywords: Biologicals, Damage Index, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2326–2351) SLE – Treatment Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: A key treatment goal for patients (pts) with SLE is to reduce use of CS, due to their association with organ damage.1 BEL is an approved treatment for active SLE and LN, in addition to standard therapy (ST).1 BEL-treated pts were able to reduce CS dose and exhibited delayed organ damage progression during long-term extension studies (LTEs).2–4 We evaluated use of SLE medications and change in organ damage over time in pts with SLE using data from three multicenter LTE studies.

Methods: This post hoc analysis pooled data from the LBSL02 LTE (Phase 2; GSK Study 112626),2 BLISS-76 LTE (US pts only; Phase 3; GSK Study 112233),3 and BLISS-52 + BLISS-76 LTE (excluding US pts from BLISS-76; Phase 3; GSK Study 112234)4 studies. To enroll in LTEs, pts must have completed treatment through Week 72 of LBSL02 and BLISS-76, or Week 48 of BLISS-52; improvement in physician global assessment at Week 72 or 68 versus at first BEL dose was required in the LBSL02 LTE. Pts received BEL 10 mg/kg intravenously every 28 days plus ST at the start of each LTE, regardless of prior drug allocation. Maximum daily equivalent prednisone dose was summarized any time post–first BEL dose (in prior trial period or LTE) and in each year. SLICC/ACR Damage Index (SDI) score was assessed among eligible pts in the BLISS-76, and BLISS-52 + BLISS-76 LTE studies; the high disease activity (HDA) population (anti-dsDNA positive and low C3/C4); and the 5-year completer population (pts with ≥5 years of SDI data post–first BEL dose).

Results: Overall, 1304 pts enrolled in the LTE studies, 1299 (99.6%) received ≥1 dose of study drug (pooled safety population) and 604 (46.5%) completed their respective studies. Cumulative BEL-treated patient-years was 7040.1. At baseline (first BEL dose in prior trial period or LTE), 1054 (81.1%) pts received CS. Over time, the proportion of pts discontinuing CS (receiving an equivalent dose of 0 mg/day) increased; the proportion receiving >0 to ≤7.5 mg/day increased up to Year 4–5 (Table 1). Any use of CS decreased over time, while use of antimalarials and immunosuppressive/immunomodulatory agents remained stable (Table 1). At baseline, 580 (58.2%) and 416 (41.8%) pts had an SDI score of zero and ≥1, respectively. Mean (standard deviation [SD]) change over time in SDI score was similar and remained low for the total, HDA, and 5-year completer populations (Table 2). Among the 5-year completer population, ≤20% had SDI worsening (change ≥0) compared with baseline in any study year (Table 3).

Conclusion: Over time, more BEL-treated pts were able to reduce their daily equivalent prednisone dose and exhibited low change in SDI. Limitations include the open-label nature of the studies, lack of control arm, and increased number of withdrawals at later years. These data are consistent with previous observations of the steroid sparing–effect of BEL, and delayed organ damage progression among a large population of BEL-treated pts.2–5 References
1 Fanouriakis A et al. Ann Rheum Dis 2019;0:1–10
2 Wallace DJ et el. Arthritis Rheumatol 2019;7:1125–34
3 Furie RA et al. Arthritis Rheumatol 2018;6:868–77
4 van Vollenhoven RF et al. Rheumatology(Oxford) 2020;2:281–91
5 Urowitz MB et al. Lupus Sci Med 2020;7:e000412

Funding: GSK

Supporting image 1

Table 1. Use of SLE medication over time* (pooled safety population, N=1299; post hoc analysis).

*Data are summarized at any time post–first BEL dose and in each year; †post–first BEL dose data include follow-up visits after the final dose of BEL; data from Year 0 up to last visit in the treatment period are shown by years of study participation; pts could be counted in more than one year interval; ‡CS were converted to a daily prednisone equivalent dose and the maximum dose was summarized in each interval; maximum daily prednisone dose applies to any time post–first BEL dose and for each year interval; baseline daily prednisone dose was calculated as the average daily dose for the 7 days pre–first BEL dose.

Supporting image 2

Table 2. Change in SDI score from baseline by belimumab visit* (N=1003; post hoc analysis).

*Observed data are presented; the SDI score is cumulative, once an item is scored, it continues to be scored at subsequent visits; for years in which a patient withdraws from the study, the exit visit assessment is used in place of the Week 48 assessment for the year, but this value is not carried forward through later years; †number of pts with available data at baseline and Week 48 yearly visit; ‡HDA is defined as anti-dsDNA positive and low C3/C4; ¶the 5-year completer population is defined as pts with ≥5 years of SDI assessment data post–first BEL dose (in prior trial period or LTE).

Supporting image 3

Table 3. Change in SDI score category from baseline by year* (5-year completer population,† N=522; post hoc analysis).

* Observed data are presented; the SDI score is cumulative, once an item is scored, it continues to be scored at subsequent visits; for years in which a patient withdraws from the study, the exit visit assessment is used in place of the Week 48 assessment for the year, and this value is not carried forward through later years; †the 5-year completer population is defined as pts with ≥5 years of SDI assessment data post–first BEL dose (in prior trial period or LTE); ‡number of pts with available data at baseline and year interval.


Disclosures: Z. Touma: AstraZeneca, 2, GSK, 2; C. Arriens: AstraZeneca, 1, 5, 6, Aurinia, 6, Bristol-Myers Squibb, 1, 5, Cabaletta, 1, GSK, 1, Kezar, 1, UCB, 1; C. Henning: GSK, 3, 11; A. Carroll: GSK, 3, 11; P. Curtis: GSK, 3, 11; R. Levy: GSK, 3, 11; W. Stohl: GSK, 5, Pfizer, 5.

To cite this abstract in AMA style:

Touma Z, Arriens C, Henning C, Carroll A, Curtis P, Levy R, Stohl W. SLE Medication Usage and Organ Damage Among Adult SLE Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/sle-medication-usage-and-organ-damage-among-adult-sle-patients-with-sle-treated-with-belimumab-bel-pooled-data-from-three-open-label-extension-studies-over-11-years/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sle-medication-usage-and-organ-damage-among-adult-sle-patients-with-sle-treated-with-belimumab-bel-pooled-data-from-three-open-label-extension-studies-over-11-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology